JP2004508415A5 - - Google Patents

Download PDF

Info

Publication number
JP2004508415A5
JP2004508415A5 JP2002526415A JP2002526415A JP2004508415A5 JP 2004508415 A5 JP2004508415 A5 JP 2004508415A5 JP 2002526415 A JP2002526415 A JP 2002526415A JP 2002526415 A JP2002526415 A JP 2002526415A JP 2004508415 A5 JP2004508415 A5 JP 2004508415A5
Authority
JP
Japan
Prior art keywords
antibody
use according
medicament
route
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002526415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/028451 external-priority patent/WO2002022166A2/en
Publication of JP2004508415A publication Critical patent/JP2004508415A/ja
Publication of JP2004508415A5 publication Critical patent/JP2004508415A5/ja
Pending legal-status Critical Current

Links

Images

JP2002526415A 2000-09-14 2001-09-12 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト Pending JP2004508415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23235500P 2000-09-14 2000-09-14
PCT/US2001/028451 WO2002022166A2 (en) 2000-09-14 2001-09-12 Tweak receptor agonists as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
JP2004508415A JP2004508415A (ja) 2004-03-18
JP2004508415A5 true JP2004508415A5 (enExample) 2008-10-23

Family

ID=22872776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526415A Pending JP2004508415A (ja) 2000-09-14 2001-09-12 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト

Country Status (9)

Country Link
EP (2) EP2260867A1 (enExample)
JP (1) JP2004508415A (enExample)
AR (1) AR030721A1 (enExample)
AT (1) ATE515271T1 (enExample)
AU (2) AU8901901A (enExample)
CA (1) CA2422095A1 (enExample)
NZ (1) NZ525140A (enExample)
TW (1) TWI275399B (enExample)
WO (1) WO2002022166A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2394015C (en) 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
AU2003224950B2 (en) * 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
JP4823060B2 (ja) 2003-07-24 2011-11-24 アムジェン インコーポレイテッド Ｔｗｅａｋ受容体のマルチマー化およびオリゴマー化可溶性断片に関する組成物および方法
EP1566636A1 (en) * 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130374A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
JP2002536968A (ja) * 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的な抗体およびその使用
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor

Similar Documents

Publication Publication Date Title
KR101905208B1 (ko) Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물
JP6215429B2 (ja) Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ
KR101733252B1 (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 멜팔란을 함유하는 항종양 조합물
JP6130871B2 (ja) Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2019502676A5 (enExample)
JP2017510559A5 (enExample)
KR20110096551A (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 시타라빈을 함유하는 항종양 조합물
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
WO2002045653A3 (en) Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
KR20100113572A (ko) 항-ＥＤｂ 피브로넥틴 항체-ＩＬ-２ 융합 단백질과 Ｂ 세포, Ｂ 세포 전구체 및/또는 이의 암성 대응물에 결합하는 분자의 조합물
AU2021271647A1 (en) Use of a multimeric anti-DR5 binding molecule in combination with a cancer therapy for treating cancer
JP2020510039A5 (enExample)
Qi et al. A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
Jabbour et al. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies
WO2019149219A1 (zh) 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用
Morgan Jr et al. Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen
Li et al. FLT3 antibody-based therapeutics for leukemia therapy
Parker et al. The Immunology of Sepsis
Carrasquillo Radioimmunotherapy of Non Hodgkins Lymphomas
Friedberg Novel Monoclonal Antibodies in the Treatment of Lymphoma
Abraham Neutralizing antibodies and receptor constructs
Fagerberg The idiotypic network response in cancer patients treated with monoclonal antibodies.
HK1185022B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib